DOI QR코드

DOI QR Code

Relationship between HER2 Proto-oncogene Status and Prognostic Factors of Breast Cancer in the West of Iran

  • Amirifard, Nasrin (Cancer Research Center, Kermanshah University of Medical Sciences) ;
  • Sadeghi, Edris (Cancer Research Center, Kermanshah University of Medical Sciences) ;
  • Payandeh, Mehrdad (Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences) ;
  • Mohebbi, Hossain (Medical Biology Research Center, Kermanshah University of Medical Sciences) ;
  • Sadeghi, Masoud (Medical Biology Research Center, Kermanshah University of Medical Sciences) ;
  • Choubsaz, Mansour (Cancer Research Center, Kermanshah University of Medical Sciences)
  • Published : 2016.02.05

Abstract

Background: Breast cancer is a very common health problem in Iranian women. The HER2-neu gene is a transmembrane receptor tyrosine kinase with homology to members of the EGF receptor family. The aim of this study was to investigate the association between HER2-neu oncogene status with prognostic factors of breast cancer in Kermanshah province, Iran. Materials and Methods: Relationship between HER2-neu and prognostic factors of 130 cases of breast cancer were evaluated during two years in Imam Reza hospital in Kermanshah, Iran. Data were analyzed using descriptive statistics and the T-test and Mann-Whitney U non-parametric test using SPSS 19. Results: The mean age for the patients was $46.0{\pm}8.0years$, all being female. Among the predictive factors for breast cancer were family history, stage of disease, involvement of the lymphovascular system, number of involved lymph nodes in axillaries, grading and hormone receptor status with HER2-neu oncogene had direct correlation and between factors, tumor location, patient age and histological characteristics and HER2-neu oncogene had no significant relationship. We found significant correlation between HER2 with ER and PR and also HER2 with ER, PR negative. Conclusions: HER2-neu is risk factor that can be a good prognostic and also predictive factor. For these reasons, we recommend that it be evaluated for all types of BC.

Keywords

Breast cancer;HER2;prognostic factors;trastuzumab

References

  1. Bailey JA (1988). Concise dictionary of medical-legal terms. New York, The Parthanon Publishing Group.
  2. Berger MS, Locher GW, Saurer S, et al (1988). Correlation of c-erb B2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res, 48, 1238-43.
  3. Chuangsuwanich T, Pongpruttipan T, O-Charoenrat P, et al (2014). Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand. Asian Pac J Cancer Prev, 15, 1187-92. https://doi.org/10.7314/APJCP.2014.15.3.1187
  4. Dawood S, Broglio K, Buzdar AU, et al (2010). Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol, 28, 92-8. https://doi.org/10.1200/JCO.2008.19.9844
  5. Dorr FA (1993). Prognostic Factors Observed in Current Clinical Trials. Cancer, 71, 2163-8. https://doi.org/10.1002/1097-0142(19930315)71:6+<2163::AID-CNCR2820711607>3.0.CO;2-W
  6. Doval DC, Sharma A, Sinha R, et al (2015). Immunohistochemical profile of breast cancer patients at a tertiary care hospital in New Delhi, India. Asian Pac J Cancer Prev, 16, 4959-64. https://doi.org/10.7314/APJCP.2015.16.12.4959
  7. Dowsett M, Dunbier A (2008). Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin Cancer Res, 14, 8019-26. https://doi.org/10.1158/1078-0432.CCR-08-0974
  8. Gullick WJ (1990). New developments in the molecular biology of breast cancer. Eur J Cancer, 26, 509-510. https://doi.org/10.1016/0277-5379(90)90026-P
  9. Hartmann LC, Ingle JN, Wold LE, et al (1994). Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer, 74, 2956-63. https://doi.org/10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V
  10. Hu P, Margolis B, Skolnik EY, et al (1992). Interaction of phosphatidylinositol 3-kinase-associated p85 with epidermal growth factor and platelet-derived growth factor receptors. Mol Cell Biol, 12, 981-90. https://doi.org/10.1128/MCB.12.3.981
  11. Ji H, Lipponen P, Aaltomaa S, et al (1993). c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Anticancer Res, 13, 1147-52.
  12. Klijin JGM (1991). Clinical parameters and symptoms for the progression to endocrine independence of breast cancer. In: mechanisms of progression to hormone-independent growth of breast and prostatic cancer. Carnfoth: The Parthenon Publishing Group, 11-9.
  13. Kurebayashi J (2007). Current clinical trials of endocrine therapy for breast cancer. Breast Cancer, 14, 200-214. https://doi.org/10.2325/jbcs.954
  14. Lehrer S, Lee P, Tartter P, Shank B, et al (1995). Breast cancer and family history: a multivariate analysis of levels of tumor HER2 protein and familyhistory of cancer in women who have breast cancer. Mt Sinai J Med, 62, 415-8.
  15. Mirtavoos Mahyari H, Khosravi A, Mirtavoos Mahyari Z, et al (2014). Overexpression of HER2/neu as a prognostic value in iranian women with early stage breast cancer; a single institute Study. Iran Red Crescent Med J, 16, 16005.
  16. Mohammadi S, Sulaiman S, Koon PB, et al (2013). Association of nutritional status with quality of life in breast cancer survivors. Asian Pac J Cancer Prev, 14, 7749-55. https://doi.org/10.7314/APJCP.2013.14.12.7749
  17. Qin T, Yuan ZY, Peng RJ, et al (2015). Clinicopathologic characteristics and prognostic factors for HER2 positive patients with metastaticbreast cancer in southern China. Arch Med Sci, 11, 544-50.
  18. Payandeh M, Sadeghi M, Sadeghi E, et al (2015). Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of womenwith invasive ductal carcinoma and triple negative breast cancer. Asian Pac J Cancer Prev, 16, 4863-7. https://doi.org/10.7314/APJCP.2015.16.12.4863
  19. Perou C, Sorlie T, Eisen M, et al (2000). Molecular portraits of human breast tumours. Nature, 406,747-52. https://doi.org/10.1038/35021093
  20. Perren TJ(1991). c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer, 63, 328-32. https://doi.org/10.1038/bjc.1991.78
  21. Olszewski WP, Szumera-Cieckiewicz A, Piechocki J, et al (2009). The characteristics of the sentinel lymph node metastasis in predicting the axillary lymph node status in patients with breast carcinoma. Pol J Pathol, 60, 138-43.
  22. Seshie B, Adu-Aryee NA, Dedey F, et al (2015). A retrospective analysis of breast cancer subtype based on ER/PR and HER2 status in Ghanaian patients at the Korle Bu Teaching Hospital, Ghana. BMC Clin Pathol, 15, 14. https://doi.org/10.1186/s12907-015-0014-4
  23. Sotiriou C, Neo S, McShane L, et al (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA, 100, 10393-8. https://doi.org/10.1073/pnas.1732912100
  24. Yan J, Liu XL, Han LZ, et al (2015). Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-${\alpha}$ expression in invasive ductal breast cancer patients and correlations with prognosis. Asian Pac J Cancer Prev, 16, 823-9. https://doi.org/10.7314/APJCP.2015.16.2.823
  25. White J, Morrow M, Moughan J, et al (2003). Compliance with breast conservation standards for patients with early stage breast carcinoma. Cancer, 97, 893-904. https://doi.org/10.1002/cncr.11141